For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
6
views
27
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      218
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Case of Iodine 125 Seeds (I-125) Responding to Lung Squamous Cell Carcinoma

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lung squamous cell cancer (SCC) and accounts for approximately 20%–30% of all lung cancers. Surgery, chemotherapy and radiotherapy are the main treatments for lung SCC patients. A case with lung SCC patient who was treated using iodine 125 seeds (I-125) because the location of the tumor was adjacent to the great vessels. I-125 is an ideal brachytherapy for lung SCC patients with large masses who lost the chance of operation. I-125 is an adjuvant therapy, combined with chemotherapy and molecular targeting therapy might serve to improve the prognosis of lung SCC patients.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          Hyuna Sung, Jacques Ferlay, Rebecca Siegel … (2021)
          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
          Article 0 comments Cited 31875 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

            Baohui Han, Kai Li, Qiming Wang … (2018)
            Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free survival with a potential benefit of overall survival, leading to the phase 3 trial to confirm the drug's efficacy in advanced non-small cell lung cancer (NSCLC).
            Article 0 comments Cited 296 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

              Yihebali Chi, Zhiwei Fang, Xiaonan Hong … (2018)
              Article 0 comments Cited 142 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Dose Response
                Journal ID (iso-abbrev): Dose Response
                Journal ID (hwp): spdos
                Journal ID (publisher-id): DOS
                Title: Dose-Response
                Publisher: SAGE Publications (Sage CA: Los Angeles, CA )
                ISSN (Electronic): 1559-3258
                Publication date (Electronic): 19 May 2022
                Publication date Collection: Apr-Jun 2022
                Volume: 20
                Issue: 2
                Electronic Location Identifier: 15593258221103373
                Affiliations
                [1 ]Department of Oncology, Ringgold 372209, universityHospital Affiliated 5 to Nantong University (Taizhou People’s Hospital); , Taizhou, China
                [2 ]Department of General Surgery, Ringgold 372209, universityHospital Affiliated 5 to Nantong University (Taizhou People’s Hospital); , Taizhou, China
                Author notes
                [*]Shengbin Dai, Department of Oncology, Jiangsu Taizhou People’s Hospital, Taizhou 225300, China. Email: 13515155717@ 123456163.com
                [#]

                These authors contributed equally to this study and share first authorship.

                Author information
                https://orcid.org/0000-0003-0263-5993
                https://orcid.org/0000-0002-4858-395X
                Article
                Publisher ID: 10.1177_15593258221103373
                DOI: 10.1177/15593258221103373
                PMC ID: 9125098
                SO-VID: 663fcc51-89c1-4752-9f99-be74ddffe3d6
                Copyright © © The Author(s) 2022
                License:

                This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ( https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ( https://us.sagepub.com/en-us/nam/open-access-at-sage).

                History
                Date received : 16 January 2022
                Date accepted : 9 May 2022
                Categories
                Subject: Clinical Case
                Custom metadata
                typesetter ts10
                cover-date April-June 2022

                Keywords: lung squamous cell carcinoma,iodine 125 seeds,chemotherapy,targeted therapy,integrated therapy
                Data availability:
                Keywords: lung squamous cell carcinoma, iodine 125 seeds, chemotherapy, targeted therapy, integrated therapy

                Comments

                Comment on this article